Literature DB >> 17370088

Serum level of arginine-vasopressin influences the prognosis of extensive-disease small-cell lung cancer.

Shigeki Umemura1, Yoshihiko Segawa, Hiroshi Ueoka, Katsuyuki Hotta, Katsuyuki Kiura, Nagio Takigawa, Masahiro Tabata, Akihiro Bessho, Tetsu Shinkai, Mitsune Tanimoto.   

Abstract

PURPOSE: The purpose of this study is to elucidate the influence of serum arginine-vasopressin (AVP) level on prognosis of extensive-disease small-cell lung cancer (ED-SCLC).
METHODS: We retrospectively investigated the clinical records of 163 patients with ED-SCLC, who were admitted to Okayama University Hospital or National Shikoku Cancer Center Hospital. The influence of 14 pretreatment variables on survival was analyzed.
RESULTS: In a multivariate analysis of 163 patients, elevation of serum LDH level (P = 0.028) and poor performance status (PS > or = 2, P = 0.002) were independent poor prognostic factors. In 34 patients whose serum AVP levels were available, high serum AVP level was related to the poor prognosis (P < 0.001). The serum-sodium level did not affect the survival. Median serum level of osmotic pressure in 34 patients was normal (284.9 mOsm/kg), although, serum osmotic pressure was low in four of six patients with high serum AVP level. In all patients with high serum AVP level, serum LDH level was elevated.
CONCLUSIONS: The data from the current study suggested that serum LDH level and PS were the poor prognostic factors for ED-SCLC. But we additionally identified the prognostic significance of serum AVP level, which may be a more useful factor than serum-sodium level.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17370088     DOI: 10.1007/s00432-007-0196-y

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.322


  31 in total

1.  Prognostic factors and prognostic staging system for small cell lung cancer.

Authors:  M Kawahara; M Fukuoka; N Saijo; Y Nishiwaki; H Ikegami; T Tamura; M Shimoyama; K Suemasu; K Furuse
Journal:  Jpn J Clin Oncol       Date:  1997-06       Impact factor: 3.019

2.  Cancer statistics, 1997.

Authors:  S L Parker; T Tong; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1997 Jan-Feb       Impact factor: 508.702

3.  A prospective study of patients with lung cancer and hyponatremia of malignancy.

Authors:  B E Johnson; J P Chute; J Rushin; J Williams; P T Le; D Venzon; G E Richardson
Journal:  Am J Respir Crit Care Med       Date:  1997-11       Impact factor: 21.405

Review 4.  Autoimmune central nervous system paraneoplastic disorders: mechanisms, diagnosis, and therapeutic options.

Authors:  E J Dropcho
Journal:  Ann Neurol       Date:  1995-05       Impact factor: 10.422

5.  Cancer statistics, 1994.

Authors:  C C Boring; T S Squires; T Tong; S Montgomery
Journal:  CA Cancer J Clin       Date:  1994 Jan-Feb       Impact factor: 508.702

6.  Evaluation of three biochemical markers for serially monitoring the therapy of small-cell lung cancer.

Authors:  P A Ganz; P Y Ma; H J Wang; R M Elashoff
Journal:  J Clin Oncol       Date:  1987-03       Impact factor: 44.544

7.  Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation.

Authors:  K Osterlind; P K Andersen
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

8.  The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer.

Authors:  A F List; J D Hainsworth; B W Davis; K R Hande; F A Greco; D H Johnson
Journal:  J Clin Oncol       Date:  1986-08       Impact factor: 44.544

9.  Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients.

Authors:  D Spiegelman; L H Maurer; J H Ware; M C Perry; A P Chahinian; R Comis; W Eaton; B Zimmer; M Green
Journal:  J Clin Oncol       Date:  1989-03       Impact factor: 44.544

10.  Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base.

Authors:  K S Albain; J J Crowley; M LeBlanc; R B Livingston
Journal:  J Clin Oncol       Date:  1990-09       Impact factor: 44.544

View more
  2 in total

1.  Circulating Levels of the Cardiovascular Biomarkers ST2 and Adrenomedullin Predict Outcome within a Randomized Phase III Lung Cancer Trial (RASTEN).

Authors:  Emelie Gezelius; Pär-Ola Bendahl; Widet Gallo; Kelin Gonçalves de Oliveira; Lars Ek; Bengt Bergman; Jan Sundberg; Olle Melander; Mattias Belting
Journal:  Cancers (Basel)       Date:  2022-03-03       Impact factor: 6.639

2.  Prevalence and Prognostic Significance of Hyponatremia in Patients With Lung Cancer: Systematic Review and Meta-Analysis.

Authors:  Eszter Bartalis; Marin Gergics; Benedek Tinusz; Mária Földi; Szabolcs Kiss; Dávid Németh; Margit Solymár; Zsolt Szakács; Péter Hegyi; Emese Mezösi; László Bajnok
Journal:  Front Med (Lausanne)       Date:  2021-12-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.